{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T22:18:39Z","timestamp":1785449919254,"version":"3.56.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,5,31]],"date-time":"2019-05-31T00:00:00Z","timestamp":1559260800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,5,31]],"date-time":"2019-05-31T00:00:00Z","timestamp":1559260800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001922","name":"Efficacy and Mechanism Evaluation Programme","doi-asserted-by":"publisher","award":["15\/178\/09"],"award-info":[{"award-number":["15\/178\/09"]}],"id":[{"id":"10.13039\/501100001922","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12876-019-0992-2","type":"journal-article","created":{"date-parts":[[2019,5,31]],"date-time":"2019-05-31T14:03:04Z","timestamp":1559311384000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Autologous stem cell transplantation in refractory Crohn\u2019s disease \u2013 low intensity therapy evaluation (ASTIClite): study protocols for a multicentre, randomised controlled trial and observational follow up study"],"prefix":"10.1186","volume":"19","author":[{"name":"on Behalf of the Autologous Stem Cell Transplantation In Refractory CD - Low Intensity Therapy Evaluation Study Investigators","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Snowden","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the European Society for Blood and Marrow Transplantation (EBMT) Autoimmune Diseases Working Party (ADWP)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Hawkey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Hind","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9443-7681","authenticated-orcid":false,"given":"Lizzie","family":"Swaby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Mellor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Emsley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Mandefield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Badoglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Polge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Labopin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Gribben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Graham","family":"Pockley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma A.","family":"Foulds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Lobo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Travis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miles","family":"Parkes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Satsangi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Papaioannou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James O.","family":"Lindsay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,31]]},"reference":[{"key":"992_CR1","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1016\/S0140-6736(16)31711-1","volume":"389","author":"J Torres","year":"2017","unstructured":"Torres J, Mehandru S, Colombel J, Peyrin-biroulet L. Seminar Crohn\u2019s disease. Lancet. 2017;389:1741\u201355.","journal-title":"Lancet."},{"issue":"4","key":"992_CR2","doi-asserted-by":"publisher","first-page":"e0142481","DOI":"10.1371\/journal.pone.0142481","volume":"11","author":"M van der Valk","year":"2016","unstructured":"van der Valk M, Mangen M, Severs M, van der Have M, Dijkstra G, van Bodegraven A, et al. Evolution of costs of inflammatory bowel disease over two years of follow-up. PLoS One. 2016;11(4):e0142481.","journal-title":"PLoS One"},{"issue":"1","key":"992_CR3","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1136\/gutjnl-2012-303376","volume":"63","author":"ME van der Valk","year":"2014","unstructured":"van der Valk ME, Mangen M-JJ, Leenders M, Dijkstra G, van Bodegraven AA, Fidder HH, et al. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNF\u03b1 therapy: results from the COIN study. Gut. 2014;63(1):72\u20139.","journal-title":"Gut."},{"key":"992_CR4","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S2468-1253(19)30012-3","volume":"4","author":"NA Kennedy","year":"2019","unstructured":"Kennedy NA, Heap GA, Green HD, Hamilton B, Bewshea C, Walker GJ, et al. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn\u2019s disease: a prospective, multicentre, cohort study. Lancet Gastroenterol Hepatol. 2019;4:341.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"8","key":"992_CR5","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1215739","volume":"369","author":"WJ Sandborn","year":"2013","unstructured":"Sandborn WJ, Feagan B, Rutgeerts P, Hanauer S, Colombel J-F, Sands BE, et al. Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease. N Engl J Med. 2013;369(8):711\u201321.","journal-title":"N Engl J Med"},{"issue":"3","key":"992_CR6","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1053\/j.gastro.2014.05.008","volume":"147","author":"BE Sands","year":"2014","unstructured":"Sands BE, Feagan BG, Rutgeerts P, Colombel J, Sandborn WJ, Sy R, et al. Effects of Vedolizumab induction therapy for patients with Crohn\u2019 s disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology. 2014;147(3):618\u2013627.e3.","journal-title":"Gastroenterology."},{"issue":"26","key":"992_CR7","doi-asserted-by":"publisher","first-page":"6123","DOI":"10.1182\/blood-2010-06-292391","volume":"116","author":"RK Burt","year":"2011","unstructured":"Burt RK, Craig RM, Milanetti F, Quigley K, Gozdziak P, Bucha J, et al. Autologous nonmyeloablative hematopoietic stem cell transplantation in patients with severe anti-TNF refractory Crohn\u2019s disease : long-term follow-up. Blood. 2011;116(26):6123\u201332.","journal-title":"Blood."},{"issue":"11","key":"992_CR8","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1093\/qjmed\/hcu095","volume":"107","author":"JA Snowden","year":"2014","unstructured":"Snowden JA, Ansari A, Sachchithanantham S, Jackson G, Thompson N, Lobo A, et al. Autologous stem cell transplantation in severe treatment-resistant Crohn\u2019s disease: long-term follow-up of UK patients treated on compassionate basis. QJM. 2014;107(11):871\u20137.","journal-title":"QJM."},{"issue":"23","key":"992_CR9","doi-asserted-by":"publisher","first-page":"2524","DOI":"10.1001\/jama.2015.16700","volume":"314","author":"CJ Hawkey","year":"2015","unstructured":"Hawkey CJ, Allez M, Clark MM, Labopin M, Lindsay JO, Ricart E, et al. Autologous Hematopoetic stem cell transplantation for refractory Crohn disease. Jama. 2015;314(23):2524.","journal-title":"Jama."},{"key":"992_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S2468-1253(16)30175-3","volume":"2","author":"JO Lindsay","year":"2017","unstructured":"Lindsay JO, Allez M, Clark M, Labopin M, Ricart E, Satsangi J, Rogler G, Rovira M, Farge D, Hawkey C, on behalf of ATG. Autologous stem \u00ad cell transplantation in treatment \u00ad refractory Crohn\u2019s disease - an analysis of pooled data from the ASTIC trial. Lancet Gastroenterol Hepatol. 2017;2:1\u20135.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"992_CR11","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1093\/ecco-jcc\/jjx180.020","volume":"12","author":"CK Brierley","year":"2018","unstructured":"Brierley CK, Castilla-llorente C, Labopin M, Badoglio M, Ricart E, Dierickx D, et al. Autologous Haematopoietic stem cell transplantation for Crohn\u2019s disease: a retrospective survey of long-term outcomes from the European Society for Blood and Marrow Transplantation. J Crohn's Colitis. 2018;12:1097\u2013103.","journal-title":"J Crohn's Colitis"},{"key":"992_CR12","unstructured":"Burt RK. Stem cell transplantation for refractory Crohn disease lung volume reduction coils for severe emphysema. 2016;2\u20133."},{"issue":"23","key":"992_CR13","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1001\/jama.2016.4033","volume":"315","author":"C Hawkey","year":"2016","unstructured":"Hawkey C, Lindsay J, Gribben J. Stem cell transplantation for refractory Crohn\u2019s disease. JAMA. 2016;315(23):2620\u20131.","journal-title":"JAMA"},{"issue":"9","key":"992_CR14","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1136\/gutjnl-2015-309836","volume":"65","author":"Aranzazu Jauregui-Amezaga","year":"2015","unstructured":"Jauregui-Amezaga A, Rovira M, Mar\u00edn P, et al. Improving safety of autologous haematopoietic stem cell transplantation in patients with Crohn\u2019s disease. Gut. 2016;65:1456-62.","journal-title":"Gut"},{"key":"992_CR15","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1093\/ecco-jcc\/jjx054","volume":"11","author":"A Lopez-Garcia","year":"2017","unstructured":"Lopez-Garcia A, Rovira M, Jauregui-Amezaga A, Marin P, Barastegui R, Salas A, et al. Autologous hematopoietic stem cell transplantation for refractory Crohn\u2019s disease - efficacy in a single Centre cohort. J Crohn's Colitis. 2017;11:1161.","journal-title":"J Crohn's Colitis"},{"issue":"6","key":"992_CR16","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1038\/bmt.2011.185","volume":"47","author":"JA Snowden","year":"2012","unstructured":"Snowden JA, Saccardi R, Allez M, Ardizzone S, Arnold R, Cervera R, et al. Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow transplantation. Bone Marrow Transplant. 2012;47(6):770\u201390.","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"992_CR17","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/sj.bmt.1704598","volume":"34","author":"M Karanth","year":"2004","unstructured":"Karanth M, Chakrabarti S, Lovell RA, Harvey C, Holder K, McConkey CC, et al. A randomised study comparing peripheral blood progenitor mobilisation using intermediate-dose cyclophosphamide plus lenograstim with lenograstim alone. Bone Marrow Transplant. 2004;34(5):399\u2013403.","journal-title":"Bone Marrow Transplant"},{"key":"992_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/sj.bmt.1703081","volume":"28","author":"RK Burt","year":"2001","unstructured":"Burt RK, Fassas A, Snowden JA, Van Laar JM, Kozak T, Wulffraat NM, et al. Collection of hematopoietic stem cells from patients with autoimmune diseases. Bone Marrow Transplant. 2001;28:1\u201312.","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"992_CR19","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1007\/s00277-012-1462-x","volume":"91","author":"H Kim","year":"2012","unstructured":"Kim H, Lee JH, Joo YD, Bae SH, Hyun MS, Lee JH, et al. A randomized comparison of cyclophosphamide vs. reduced dose cyclophosphamide plus fludarabine for allogeneic hematopoietic cell transplantation in patients with aplastic anemia and hypoplastic myelodysplastic syndrome. Ann Hematol. 2012;91(9):1459\u201369.","journal-title":"Ann Hematol"},{"issue":"1","key":"992_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12874-017-0388-3","volume":"17","author":"F Lauzier","year":"2017","unstructured":"Lauzier F, Adhikari NK, Seely A, Koo KKY, Belley-C\u00f4t\u00e9 EP, Burns KEA, et al. Protocol adherence for continuously titrated interventions in randomized trials: an overview of the current methodology and case study. BMC Med Res Methodol. 2017;17(1):1\u20136.","journal-title":"BMC Med Res Methodol"},{"issue":"6","key":"992_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0155856","volume":"11","author":"G Cosma","year":"2016","unstructured":"Cosma G, Acampora G, Brown D, Rees RC, Khan M, Pockley AG. Prediction of pathological stage in patients with prostate cancer: A neuro-fuzzy model. PLoS One. 2016;11(6):1\u201327.","journal-title":"PLoS One"},{"key":"992_CR22","doi-asserted-by":"publisher","first-page":"646","DOI":"10.3389\/fimmu.2018.00646","volume":"9","author":"AG Pockley","year":"2018","unstructured":"Pockley AG, Lindsay JO, Foulds GA, Rutella S, Gribben J, Alexander T, et al. Immune reconstitution after autologous hematopoietic stem cell transplantation in Crohn\u2019s disease: current status and future directions. A review on behalf of the EBMT autoimmune diseases working party and the autologous stem cell transplantation in Refra. Front Immunol. 2018;9:646.","journal-title":"Front Immunol"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-019-0992-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12876-019-0992-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-019-0992-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,29]],"date-time":"2020-05-29T23:11:33Z","timestamp":1590793893000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-019-0992-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,31]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["992"],"URL":"https:\/\/doi.org\/10.1186\/s12876-019-0992-2","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,31]]},"assertion":[{"value":"12 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 information"}},{"value":"The ASTIClite RCT was given approval by London \u2013 Chelsea Research Ethics Committee (17\/LO\/1690) and the EBMT follow up study by North West \u2013 Greater Manchester East Research Ethics Committee (17\/NW\/1669). The ASTIClite RCT also received Medicines and Healthcare products Regulatory Agency (MHRA) clinical trials authorisation (14620\/0051\/001\u20130001). Written informed consent will be obtained from all participants for both the RCT and follow up study prior to any study-specific procedures. Any amendments will receive ethics approval (and MHRA approval where required), and will be disseminated to investigators and site staff, who will re-consent participants if needed.The clinical sites taking part in the study are: Barts Health NHS Trust, Sheffield Teaching Hospitals NHS Foundation Trust, Nottingham University Hospitals NHS Foundation Trust, Cambridge University Hospitals NHS Foundation Trust, Oxford University Hospitals NHS Foundation Trust, NHS Lothian, Royal Liverpool & Broadgreen University Hospitals NHS Foundation Trust, Guy\u2019s & St Thomas\u2019 NHS Foundation Trust, King\u2019s College Hospital NHS Foundation Trust.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JAS declares financial support for speaking at educational events supported by Janssen, Jazz Pharma, Mallinckrodt, is a member of a trial IDMC for Kiadis Pharma. No other competing interests were declared by named authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"82"}}